Pharmaceutical

Nuvectis receives orphan drug designation for cholangiocarcinoma therapy

Nuvectis Pharma has received US Food and Drug Administration (FDA) orphan drug designation for NXP800 to treat cholangiocarcinoma.

Aug 18, 2023 - 20:00
Nuvectis receives orphan drug designation for cholangiocarcinoma therapy
Nuvectis Pharma has received US Food and Drug Administration (FDA) orphan drug designation for NXP800 to treat cholangiocarcinoma.
Read the original article

Tags:

Previous Article

EMA accepts for review Iveric Bio’s MAA for geographic atrophy therapy

Next Article

US Appeals court rules in favour of further abortion pill restrictions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: L...

Nov 4, 2023

Opinion: Do celebrity vaccine endorsements like Travis Kelce’s actually change behavior?

Opinion: Do celebrity vaccine endorsements like Travis ...

Nov 3, 2023

FDA approves import of French drug for syphilis amidst wider drug shortages

FDA approves import of French drug for syphilis amidst ...

Jan 11, 2024